Regeneron CEO: Anticipating PCSK9 launch, but worried about pricing debate

Regeneron ($REGN) is charging toward an FDA submission for its cholesterol-fighting drug candidate alirocumab. And in hopes of approval, it's working on launch plans with partner Sanofi ($SNY). But in the meantime, CEO Leonard Schleifer says he's worried that the brouhaha over drug prices might undermine Regeneron's pricing power. Report

Suggested Articles

Rather than accept a filing based on phase 1/2 data, the FDA wants Novartis to run a phase 3 for a market-expanding version of gene therapy Zolgensma.

After sifting through the data, one analyst figures the latest Opdivo-Keytruda showdown in kidney cancer might come down to commercial execution.

Call it a fall sports bounce. TV ad spending bumped up in August with the partial return of professional sports, and that included pharma buyers.